CNTX-4975 Emerging Drug Insight and Market Forecast - 2032

This “CNTX-4975 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about CNTX-4975 for osteoarthritis in the six major markets. A detailed picture of the CNTX-4975 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the CNTX-4975 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CNTX-4975 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary

Centrexion Therapeutics' lead product candidate, CNTX-4975, is being evaluated for the treatment of moderate to severe pain of knee OA. CNTX-4975 is an ultra-pure, synthetic form of trans-capsaicin injected directly into the pain site. It harnesses the natural analgesic power of capsaicin to develop a proprietary injectable therapy designed to provide fast-acting, durable and targeted pain relief.

The TRPV1 receptor that selectively inactivates local pain fibers transmitting pain signals to the brain is targeted by CNTX-4975, potentially providing relief that can last up to 6 months until local pain fibers are regenerated. CNTX-4975 manages pain without disrupting other nerve functions through its targeted delivery and highly-selective method of action.

Additionally, three Phase III clinical trials, namely VICTORY-1, VICTORY-2, and VICTORY-3 studies, are in progress for CNTX-4975 examining capsaicin and its potential to provide extended relief from knee OA. Apart from that, the company is also evaluating the other product CNTX-6970 (CCR2 antagonist) in Phase IIa for OA pain.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CNTX-4975 description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on CNTX-4975 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CNTX-4975 research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around CNTX-4975.
• The report contains forecasted sales of CNTX-4975 for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for CNTX-4975 in osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CNTX-4975 Analytical Perspective

In-depth CNTX-4975 Market Assessment

This report provides a detailed market assessment of CNTX-4975 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

CNTX-4975 Clinical Assessment

The report provides the clinical trials information of CNTX-4975 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CNTX-4975 dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to CNTX-4975 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CNTX-4975 in osteoarthritis.
• This in-depth analysis of the forecasted sales data of CNTX-4975 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CNTX-4975 in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of CNTX-4975?
• What is the clinical trial status of the study related to CNTX-4975 in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CNTX-4975 development?
• What are the key designations that have been granted to CNTX-4975 for osteoarthritis?
• What is the forecasted market scenario of CNTX-4975 for osteoarthritis?
• What are the forecasted sales of CNTX-4975 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to CNTX-4975 for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

This product will be delivered within 2 business days.